摘要:
Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T 1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86 Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
摘要:
The present invention provides radiolabeled compounds of formulae (VII) and (VIII) comprising a urea derivative, a linker, a metal chelating group, and a radiolabeled or isotopically labelled metal, pharmaceutical compositions comprising such radiolabeled compounds and methods of detecting PSMA expressing tumors. The compounds of the invention are useful for providing diagnosis of cancer.
摘要:
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
摘要:
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
摘要:
The present invention provides a compound contains a PSMA binding Lys-Glu urea moiety linked to DOTA in complex with 111 In 3+ and its use in imaging PSMA cells.
摘要:
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, ad tumor mapping are also described.
摘要:
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
摘要:
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.